`
`
`
`
`
`IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`Adam R. Brausa (Reg. No.
`60,287)
`Daralyn J. Durie (Pro Hac Vice
`to be filed)
`DURIE TANGRI LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`
`Filed on behalf of Patent Owner Genentech, Inc. by:
`
`David L. Cavanaugh (Reg. No. 36,476)
`Rebecca A. Whitfield (Reg. No. 73,756)
`Robert J. Gunther, Jr. (Pro Hac Vice to be filed)
`Lisa J. Pirozzolo (Pro Hac Vice to be filed)
`Kevin S. Prussia (Pro Hac Vice to be filed)
`Andrew J. Danford (Pro Hac Vice to be filed)
`WILMER CUTLER PICKERING
` HALE AND DORR LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________________
`
`BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`____________________________________________
`
`Case IPR2017-02031
`Patent No. 6,407,213
`____________________________________________
`
`PATENT OWNER’S PRELIMINARY RESPONSE
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`TABLE OF CONTENTS
`
`I.
`II.
`
`Page
`INTRODUCTION ........................................................................................... 1
`BACKGROUND ............................................................................................. 3
`A.
`The Invention of the ’213 Patent ........................................................... 3
`B.
`Prosecution History ............................................................................... 4
`C. Other IPR Petitions Involving the ’213 Patent ...................................... 5
`D.
`The Redundant Boehringer Petitions .................................................... 9
`III. ARGUMENT ................................................................................................. 10
`A.
`The Board Should Deny Institution of Grounds 1-3 and 5 Because
`the Board is Already Considering Those Same Grounds in the
`Ongoing Celltrion and Pfizer IPRs ..................................................... 12
`The Board Should Deny Institution of Grounds 4 and 6 Because
`the PTO Already Considered the Cited References During the
`’213 Original Prosecution ................................................................... 15
`Inter Partes Review Proceedings Violate the Constitution ................. 16
`C.
`IV. CONCLUSION .............................................................................................. 17
`
`B.
`
`
`
`
`
`
`
`i
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`TABLE OF AUTHORITIES
`
` Page(s)
`
`Federal Cases
`Cultec, Inc. v. Stormtech LLC,
`IPR2017-00777, Paper 7 (Aug. 22, 2017) .......................................................... 10
`Google Inc. v. Personal Web Techs., LLC,
`IPR2014-00980, Paper 10 (Oct. 30, 2014) ......................................................... 14
`Harmonic Inc. v. Avid Tech., Inc.,
`815 F.3d 1356 (Fed. Cir. 2016) .......................................................................... 10
`Hospira, Inc. v. Genentech, Inc.,
`IPR2017-00739, Paper 16 (July 27, 2017) ................................................... 11, 13
`Markman v. Westview Instruments, Inc.,
`517 U.S. 370 (1996) ............................................................................................ 16
`McCormick Harvesting Mach. Co. v. C. Aultman & Co.,
`169 U.S. 606 (1898) ............................................................................................ 16
`Neil Ziegmann N.P.Z., Inc. v. Stephens,
`IPR2015-01860, Paper 13 (Sept. 6, 2017) .................................................... 11, 16
`R.J. Reynolds Vapor Co. v. Fontem Holdings 1 B.V.,
`IPR2017-01118 and IPR2017-01119, Paper 8 (Oct. 4, 2017) ............................ 13
`Unified Patents, Inc. v. Berman,
`IPR2016-01571, Paper 10 (Dec. 14, 2016)......................................................... 11
`Federal Statutes
`35 U.S.C. § 325(d) ............................................................................................passim
`Regulations
`37 C.F.R. § 42.24(d) ................................................................................................ 19
`37 C.F.R. § 42.122 ................................................................................................... 14
`
`ii
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`Constitutional Provisions
`U.S. Const. Amendment VII .................................................................................... 16
`
`iii
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`Genentech, Inc. (“Patent Owner” or “Genentech”) submits this Preliminary
`
`Response to the Petition that Boehringer Ingelheim Pharmaceuticals, Inc.
`
`(“Petitioner” or “Boehringer”) filed challenging certain claims of U.S. Patent No.
`
`6,407,213 (“the ’213 patent”) (Paper 2).
`
`
`
`INTRODUCTION
`On December 1, 2017, the Board instituted four IPRs in which Celltrion,
`
`Inc. (IPR2017-01373 and IPR2017-01374) and Pfizer, Inc. (IPR2017-01488 and
`
`IPR2017-01489) have challenged numerous claims of the ’213 patent (based on a
`
`total of 32 separate grounds). Patent Owner’s responses in those proceedings are
`
`due on February 15, 2018.
`
`More than three months after Celltrion and Pfizer filed their now-instituted
`
`petitions, Boehringer filed the present Petition (and a second petition in IPR2017-
`
`02032). The Board should deny institution of the Boehringer petitions under 35
`
`U.S.C. § 325(d) for at least two reasons.
`
`First, Boehringer copied Grounds 1-3 and 5 of this Petition from IPR2017-
`
`01374 (Celltrion) and IPR2017-01488 (Pfizer), and copied Grounds 1-5 of
`
`IPR2017-02032 from IPR2017-01373 (Celltrion) and IPR2017-01489 (Pfizer)—
`
`without seeking joinder with those earlier-filed proceedings. Boehringer thus asks
`
`the Board to institute its IPRs on the same grounds already instituted in the
`
`Celltrion and Pfizer proceedings—but on a schedule trailing those proceedings by
`
`1
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`several months. This redundancy would waste the Board’s and Patent Owner’s
`
`resources, and also would unfairly allow Boehringer to preview the parties’
`
`arguments before having to address them itself. Given this resulting waste and
`
`prejudice, institution of Grounds 1-3 and 5 of this Petition (and Grounds 1-5 of
`
`IPR2017-02032) should be denied.
`
`Second, Boehringer’s remaining Grounds 4 and 6 in this proceeding are
`
`based on a 1986 article by Jones et al. (Ex. 1033) (“Jones”) and a 1988 article by
`
`Riechmann et al. (Ex. 1069) (“Riechmann”). But those grounds are not “new” at
`
`all. To the contrary, both references are discussed in the ’213 specification, and
`
`during prosecution of the ’213 patent, Patent Owner brought both references to the
`
`Patent and Trademark Office’s (“PTO”) attention on several occasions and
`
`specifically overcame an obviousness rejection based on Riechmann. As such,
`
`because the PTO has already found the challenged ’213 claims patentable over
`
`both cited references, the Board should reject Boehringer’s invitation to second-
`
`guess this prior patentability determination by denying institution of Grounds 4 and
`
`6.
`
`Patent Owner therefore respectfully requests that the Board exercise its
`
`discretion and deny institution of all grounds pursuant to Section 325(d).
`
`2
`
`
`
`
`
`
` BACKGROUND
`A. The Invention of the ’213 Patent
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`In the early 1990s, the field of therapeutic antibodies was still in its infancy.
`
`Although scientists had known since the 1970s how to obtain antibodies from
`
`animals (e.g., mice) that would bind to specific targets, those antibodies generally
`
`could not be used in humans because, over time, the body’s own immune system
`
`would attack and inactivate them (known as an “immunogenic” response). (Ex.
`
`1001 at 1:52-58.)
`
`Beginning in the late 1980s, a few scientists created “humanized” antibodies
`
`that incorporated the binding site from a non-human antibody into a human
`
`antibody framework—which they hoped might address the immunogenicity
`
`problem by reducing the amount of non-human amino acid sequences in the
`
`antibody. But those early humanized antibodies suffered from reduced binding
`
`affinity and/or still produced an immunogenic response. (Id. at 2:21-35, 3:50-55.)
`
`The ’213 inventors, Drs. Paul Carter and Leonard Presta, at Genentech
`
`developed a new “consensus human sequence” approach to humanizing antibodies
`
`that solved the prior art binding and immunogenicity problems of other humanized
`
`antibodies. (Id. at 11:32-38.) That “consensus” approach involved a single human
`
`amino acid sequence that could be used for any humanized antibody of a particular
`
`immunoglobulin subclass or subunit structure (e.g., light chain κ1). (Id. at 16:20-
`
`3
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`22 (“All of the humanized antibody models of this invention are based on a single
`
`three-dimensional computer graphics structure hereafter referred to as the
`
`consensus structure.”).) Drs. Carter and Presta also identified specific amino acids
`
`important to maintaining binding affinity. (Id. at 20:32-35.)
`
`The ’213 challenged claims are directed to humanized variable domains or
`
`humanized antibodies containing certain specified amino acid substitutions
`
`identified using the inventors’ novel consensus sequence approach.
`
`B.
`
`Prosecution History
`
`The ’213 patent is a continuation-in-part of an application filed on June 14,
`
`1991. (Ex. 1001, coversheet.) During prosecution, Patent Owner presented, and
`
`the PTO considered, a number of references describing humanized antibodies,
`
`including each of the references relied upon by Boehringer in its petitions.
`
`For example, the ’213 specification discussed both Jones and Riechmann at
`
`length, including by explaining that the references describe “substitut[ing] rodent
`
`CDRs or CDR sequences for the corresponding segments of a human antibody.”
`
`(Ex. 1001 at 2:20-28.) The specification further contrasts Jones’s approach of
`
`“substituting CDRs from rodent antibodies for the human CDRs in human
`
`frameworks [which was] sufficient to transfer high antigen binding affinity,” with
`
`Riechmann’s disclosure that it was “necessary to additionally replace one . . .
`
`framework region (FR) residue[].” (Id. at 2:53-61.)
`
`4
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`Moreover, during prosecution, Patent Owner raised Jones in overcoming a
`
`written description rejection (Ex. 1002 at 370), and overcame an obviousness
`
`rejection based on Riechmann (id. at 253-54 (Examiner asserting that Riechmann
`
`teaches “altering the sequence of the antibody to restore packing or to increase
`
`binding affinity”); id. at 372-74 (Patent Owner addressing rejection based in part
`
`on Riechmann); id. at 508-11 (Examiner no longer raising Riechmann rejection).)
`
`The Examiner ultimately allowed the challenged claims to issue over Jones and
`
`Reichmann.
`
`During prosecution of the ’213 patent, the Examiner also raised U.S. Patent
`
`No. 5,530,101 (“the ’101 patent”) (which Boehringer relies upon in IPR2017-
`
`02032) as a Section 102(e) reference and initially rejected several ’213 claims
`
`based on it. (E.g., Ex. 1002 at 739-40.) In response, Patent Owner explained how
`
`the Examiner had misconstrued the teachings of the ’101 patent and submitted a
`
`joint affidavit from Drs. Carter and Presta to antedate the ’101 patent. (Id. at 793,
`
`802-07.) The Examiner allowed the claims to issue over the ’101 patent after
`
`accepting that antedation evidence. (Id. at 813.)
`
`C. Other IPR Petitions Involving the ’213 Patent
`
`In August 2016, Mylan Pharmaceuticals, Inc. challenged the ’213 patent in
`
`two separate IPRs (IPR2016-01693 and IPR2016-01694), which the Board
`
`terminated after settlement in March 2017. (IPR2016-01693, Paper 24 (Mar. 3,
`
`5
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`2017); IPR2016-01694, Paper 23 (Mar. 3, 2017).) In May 2017, Celltrion and
`
`Pfizer each filed “copy-cat” petitions of the two original Mylan petitions.
`
`(IPR2017-01373 (Celltrion); IPR2017-01374 (Celltrion); IPR2017-01488 (Pfizer);
`
`IPR2017-01489 (Pfizer).)
`
`As shown in the table below, the copy-cat Celltrion IPR2017-01373 and
`
`Pfizer IPR2017-01489 proceedings assert identical grounds based on six
`
`references, including a 1989 article (“Queen 1989”), a PCT application published
`
`on July 26, 1990 (“Queen 1990”), the Protein Data Bank Database (“PDB
`
`Database”), a 1990 article (“Tramontano”), a 1987 reference book (“Kabat 1987”),
`
`and a March 1989 publication (“Hudziak”):
`
`Ground
`
`1
`
`2
`
`3
`
`4
`
`Claims and Basis
`IPR2017-01373 (Celltrion)
`IPR2017-01489 (Pfizer)
`Claims 1, 2, 12, 25, 29, 63, 64, 66,
`Claims 1, 2, 12, 25, 29, 63, 66, 67,
`67, 71-81
`69, 71-81
` Queen 1989
` Queen 1989
` PDB Database
` PDB Database
`
`Claims 1, 2, 4, 12, 25, 29, 62-67,
`69, 71-81
` Queen 1990
` PDB Database
`
`Claims 65, 75-77, 79
` Queen 1989
` PDB Database
` Tramontano
`
`Claims 65, 75-77, 79
` Queen 1990
`
`Claims 65, 75-77, 79
` Queen 1989
` PDB Database
` Tramontano
`
`Claims 65, 75-77, 79
` Queen 1990
`
`Claims 1, 2, 4, 12, 25, 29, 62-64,
`66, 67, 69, 71-81
` Queen 1990
` PDB Database
`
`6
`
`
`
`
`
`
`
`
`
`5
`
`6
`
`7
`
` PDB Database
` Tramontano
`
`Claims 4, 62, 64, 69
` Queen 1989
` PDB Database
` Kabat 1987
`
`Claims 30, 31, 42, 60
` Queen 1989
` PDB Database
` Hudziak
`
`Claims 30, 31, 33, 42, 60
` Queen 1990
` PDB Database
` Hudziak
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
` PDB Database
` Tramontano
`
`Claims 4, 62, 64, 69
` Queen 1989
` PDB Database
` Kabat 1987
`
`Claims 30, 31, 42, 60
` Queen 1989
` PDB Database
` Hudziak
`
`Claims 30, 31, 33, 42, 60
` Queen 1990
` PDB Database
` Hudziak
`
`In the other two copy-cat proceedings, Celltrion IPR2017-01374 and Pfizer
`
`IPR2017-01488 assert similar grounds based on seven references, including a
`
`European patent application published on December 19, 1990 (“Kurrle”), Queen
`
`1990, a 1983 publication (“Furey”), a 1987 publication (“Chothia & Lesk”), a 1985
`
`publication (“Chothia 1985”), and Hudziak:
`
`Ground
`
`1
`
`2
`
`3
`
`Claims and Basis
`IPR2017-01374 (Celltrion)
`IPR2017-01488 (Pfizer)
`Claims 1, 2, 25, 29, 63, 66, 67, 71,
`Claims 1, 2, 25, 29, 63, 66, 71,
`72, 75, 76, 80, 81
`75, 76, 78, 80, 81
` Kurrle
` Kurrle
`
`Claims 1, 2, 4, 29, 62-64, 80, 81
` Queen 1990
`
`Claims 1, 2, 4, 25, 29, 62-64, 66, Claims 1, 2, 4, 25, 29, 62-64, 66,
`
`Claims 1, 2, 4, 29, 62-64, 80, 81
` Queen 1990
`
`7
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`67, 69, 71, 72, 75, 76, 78, 80, 81
` Queen 1990
` Kurrle
`
`67, 69, 71, 72, 75, 76, 78, 80, 81
` Queen 1990
` Kurrle
`
`Claim 12
` Queen 1990
` Kurrle
` Furey
`
`Claims 65, 73, 74, 77, 79
` Queen 1990
` Kurrle
` Chothia & Lesk
` Chothia 1985
`
`Claims 30, 31, 33
` Queen 1990
` Hudziak
`
`Claim 42
` Queen 1990
` Kurrle
` Hudziak
` Furey
`
`Claim 60
` Queen 1990
` Hudziak
` Chothia & Lesk
`
`
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`Claim 12
` Queen 1990
` Kurrle
` Furey
`
`Claims 73, 77
` Queen 1990
` Kurrle
` Chothia & Lesk
`
`
`Claim 74
` Queen 1990
` Kurrle
` Chothia 1985
`
`Claims 65, 79
` Queen 1990
` Kurrle
` Chothia & Lesk
` Chothia 1985
`
`Claims 30, 31, 33, 42
` Queen 1990
` Hudziak
`
`Claim 42
` Queen 1990
` Hudziak
` Furey
`
`Claim 60
` Queen 1990
` Hudziak
`
`10
`
`
`
`8
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
` Chothia & Lesk
`
`
`On December 1, 2017, the Board instituted IPRs on all grounds recited in the
`
`four Celltrion and Pfizer petitions. (IPR2017-01373 (Paper 16); IPR2017-01374
`
`(Paper 15); IPR2017-01488 (Paper 27); IPR2017-01489 (Paper 27).) Patent
`
`Owner’s response in those proceedings is due on or before February 15, 2018.
`
`In September 2017, Samsung Bioepis also filed copy-cat petitions of the
`
`Mylan/Celltrion/Pfizer petitions (IPR2017-02139 and IPR2017-02140). Unlike
`
`Boehringer, however, Samsung filed motions seeking to join its petitions with the
`
`earlier-filed Pfizer proceedings. (IPR2017-02139, Paper 3; IPR2017-02140, Paper
`
`3.) Samsung’s motions remain pending.
`
`D. The Redundant Boehringer Petitions
`
`Boehringer filed its two petitions on August 31, 2017—i.e., over seven
`
`months after Genentech filed its December 2016 Patent Owner’s Preliminary
`
`Response in the original Mylan proceedings, over three months after Celltrion and
`
`Pfizer filed their petitions, and without any explanation as to why it could not have
`
`filed its petitions earlier. As shown in the chart below, Boehringer asserts the
`
`following grounds of unpatentability in this proceeding:
`
`Ground
`1
`
`Claims and Basis
`Claims 1, 2, 25, 29, 63, 66, 71, 75, 76, 78, 80, 81
` Kurrle
`
`
`9
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`2
`
`3
`
`4
`
`5
`
`6
`
`Claims 1, 2, 4, 29, 62-64, 80, 81
` Queen 1990
`
`Claims 1, 2, 4, 25, 29, 62-64, 66, 67, 69, 71, 72, 75, 76, 78, 80, 81
` Kurrle
` Queen 1990
`
`Claims 1, 2, 4, 25, 29, 62, 64, 66, 69, 71, 73, 75-78, 80, 81
` Jones
`
`Claims 73 and 77
` Queen 1990
` Kurrrle
` Chothia & Lesk
`
`Claim 63
` Jones
` Riechmann
`
`
`(Paper 2 at 4.)
` ARGUMENT
`Under 35 U.S.C. § 325(d), the Board may exercise its discretion to deny
`
`institution where “the same or substantially the same prior art or arguments
`
`previously were presented to the Office.” Id.; see Harmonic Inc. v. Avid Tech.,
`
`Inc., 815 F.3d 1356, 1367 (Fed. Cir. 2016) (“[T]he PTO is permitted, but never
`
`compelled, to institute an IPR proceeding.”); Cultec, Inc. v. Stormtech LLC,
`
`IPR2017-00777 (Aug. 22, 2017) (Paper 7) (designated as informative) (exercising
`
`discretion to deny institution where same prior art and arguments were presented to
`
`the PTO).
`
`10
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`Where a petitioner raises substantially the same prior art or arguments that
`
`were previously raised to the examiner or the Board, the patent owner’s interests in
`
`avoiding harassment and the Board’s interests in conserving resources often
`
`outweigh the petitioner’s desire to be heard. See Hospira, Inc. v. Genentech, Inc.,
`
`IPR2017-00739, Paper 16 at 16-18 (July 27, 2017) (designated as informative)
`
`(explaining considerations under Section 325(d)); Unified Patents, Inc. v. Berman,
`
`IPR2016-01571, Paper 10 (Dec. 14, 2016) (designated as informative) (same); Neil
`
`Ziegmann N.P.Z., Inc. v. Stephens, IPR2015-01860, Paper 13 at 6-14 (Sept. 6,
`
`2017) (expanded PTAB panel) (explaining the rationale and purpose of § 325(d)).
`
`As detailed below, four of Boehringer’s six asserted grounds (1-3 and 5)
`
`duplicate grounds that the Board has already instituted in the Celltrion and Pfizer
`
`proceedings, and the remaining two grounds (4 and 6) assert prior art that the PTO
`
`already considered when issuing the claims. Because the Board’s and Patent
`
`Owner’s interests in avoiding duplicative challenges far outweigh any interest
`
`Boehringer has in retreading these grounds, and because Patent Owner would be
`
`prejudiced if Boehringer is permitted to proceed separately on the same grounds at
`
`11
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`issue in other proceedings, institution of all grounds should be denied pursuant to
`
`Section 325(d).1
`
`A. The Board Should Deny Institution of Grounds 1-3 and 5 Because
`the Board is Already Considering Those Same Grounds in the
`Ongoing Celltrion and Pfizer IPRs.
`
`As shown in the chart below, four of Boehringer’s grounds (1-3 and 5) are
`
`essentially identical to those already instituted in the Celltrion and Pfizer IPRs (the
`
`few minor differences are underlined):
`
`Ground
`
`1
`
`2
`
`3
`
`5
`
`IPR2017-02031
`(Boehringer)
`Claims 1, 2, 25, 29,
`63, 66, 71, 75, 76, 78,
`80, 81
` Kurrle
`
`Claims 1, 2, 4, 29, 62-
`64, 80, 81
` Queen 1990
`
`Claims 1, 2, 4, 25, 29,
`62-64, 66, 67, 69, 71,
`72, 75, 76, 78, 80, 81
` Queen 1990
` Kurrle
`
`Claims 73, 77
`
`IPR2017-01374
`(Celltrion)
`Claims 1, 2, 25, 29,
`63, 66, 71, 75, 76, 78,
`80, 81
` Kurrle
`
`IPR2017-01488
`(Pfizer)
`Claims 1, 2, 25, 29,
`63, 66, 67, 71, 72, 75,
`76, 80, 81
` Kurrle
`
`Claims 1, 2, 4, 29, 62-
`64, 80, 81
` Queen 1990
`
`Claims 1, 2, 4, 25, 29,
`62-64, 66, 67, 69, 71,
`72, 75, 76, 78, 80, 81
` Queen 1990
` Kurrle
`
`Claims 65, 73, 74, 77, Claims 73, 77
`
`Claims 1, 2, 4, 29, 62-
`64, 80, 81
` Queen 1990
`
`Claims 1, 2, 4, 25, 29,
`62-64, 66, 67, 69, 71,
`72, 75, 76, 78, 80, 81
` Queen 1990
` Kurrle
`
`
`1
`For this preliminary response, Patent Owner has only presented argument
`
`under Section 325(d). Should the Board institute any aspect of this Petition, Patent
`
`Owner will present arguments on the merits at that time.
`
`12
`
`
`
`
`
`
`
` Queen 1990
` Kurrle
` Chothia & Lesk
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
` Queen 1990
` Kurrle
` Chothia & Lesk
`
`
`
`
`79
` Queen 1990
` Kurrle
` Chothia & Lesk
` Chothia 1985
`
`
`Specifically, Boehringer’s Grounds 1-3 and 5 raise the same prior art (Kurrle (Ex.
`
`1071), Queen 1990 (Ex. 1050), and Chothia & Lesk (Ex. 1062)), and challenge the
`
`same claims as Celltrion IPR2017-01374 and Pfizer IPR2017-01488 (claims 1, 2,
`
`4, 25, 29, 62-64, 66, 67, 69, 71-73, 75-78, 80, 81). The only difference is that, for
`
`certain grounds, Celltrion and Pfizer have asserted invalidity of additional claims
`
`that Boehringer has not challenged.
`
`Thus, because Boehringer’s Grounds 1-3 and 5 are wholly redundant of the
`
`already-instituted grounds in the Celltrion and Pfizer IPRs, instituting an IPR on
`
`those same grounds in this proceeding would unnecessarily waste both the Board’s
`
`and Patent Owner’s resources. See R.J. Reynolds Vapor Co. v. Fontem Holdings 1
`
`B.V., IPR2017-01118 and IPR2017-01119, Paper 8 at 4 (Oct. 4, 2017) (denying
`
`institution where “[t]he asserted art is identical to that presented in the earlier inter
`
`partes reviews”); Hospira, IPR2017-00739, Paper 16 at 18 (recognizing interests
`
`“in conserving the resources of the Office and granting patent owners repose on
`
`issues and prior art that have been considered previously” (citation omitted)).
`
`13
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`Denying institution also is necessary to protect Patent Owner from the
`
`significant prejudice that would result if Boehringer’s later-filed petition is
`
`instituted. Over the last eighteen months, Boehringer could have sought to join the
`
`earlier-filed Mylan, Celltrion, and/or Pfizer petitions, including after the Board
`
`instituted the Celltrion and Pfizer decisions on December 1, 2017. But Boehringer
`
`declined to do so (offering no explanation for its delay), and the time for joinder
`
`has now passed. See 37 C.F.R. § 42.122 (providing that “[a]ny request for joinder
`
`must be filed . . . no later than one month after the institution date of any inter
`
`partes review for which joinder is requested”); see also Google Inc. v. Personal
`
`Web Techs., LLC, IPR2014-00980, Paper 10 at 4-5 (Oct. 30, 2014) (denying
`
`untimely motion for joinder).
`
`By failing to seek joinder, Boehringer essentially asks for an unfair tactical
`
`advantage—one that would allow it to preview all of Patent Owner’s arguments
`
`and evidence in the Celltrion and Pfizer IPRs (Patent Owner’s Responses are due
`
`on February 15, 2018) well before they are presented in this proceeding. The
`
`Board should not allow Boehringer to engage in that sort of gamesmanship,
`
`particularly when coupled with the inherent inefficiency that would result by
`
`proceeding on the same grounds already instituted in the Celltrion and Pfizer IPRs.
`
`Patent Owner therefore requests that the Board deny institution of Grounds 1-3 and
`
`5 for these reasons as well.
`
`14
`
`
`
`
`
`B.
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`The Board Should Deny Institution of Grounds 4 and 6 Because
`the PTO Already Considered the Cited References During the
`’213 Original Prosecution.
`
`Boehringer bases Ground 4 on Jones, and Ground 6 on Jones in combination
`
`with Riechmann. Boehringer fails to acknowledge in its Petition that Patent Owner
`
`already presented these references during prosecution and after fully considering
`
`them, the PTO allowed the claims. In particular, Patent Owner discussed both
`
`references at length in the ’213 patent specification. (Ex. 1001 at 2:20-26
`
`(explaining that Jones and Riechmann describe “substitut[ing] rodent CDRs or
`
`CDR sequences for the corresponding segments of a human antibody”); id. at 2:53-
`
`61 (explaining in Jones, “substituting CDRs from rodent antibodies for the human
`
`CDRs in human frameworks [was] sufficient to transfer high antigen binding
`
`affinity,” and in Riechmann it was “necessary to additionally replace one . . .
`
`framework region (FR) residue[]”).)
`
`Patent Owner also addressed Jones and Riechmann in responding to PTO
`
`office actions during prosecution. For example, in overcoming a written
`
`description rejection, Patent Owner pointed to Jones as describing an antibody
`
`candidate for humanization using the invention of the ’213 patent. (Ex. 1003 at
`
`370.) And Patent Owner overcame obviousness rejections that the Examiner
`
`raised based on Riechmann. (Ex. 1002 at 253-54, 386-87, 416-17 (Examiner
`
`asserting that Riechmann teaches “altering the sequence of the antibody to restore
`
`15
`
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`packing or to increase binding affinity”); id. at 372-74, 431-35 (Patent Owner
`
`addressing rejection based in part on Riechmann); id. at 508-11 (Examiner no
`
`longer raising Riechmann rejection).) See also Application of Flint, 330 F.2d 363,
`
`365 n.1 (C.C.P.A. 1964) (“[W]ithdrawal of a reference upon which a rejection is
`
`based unequivocally withdraws that rejection.”).
`
`Because both Jones and Riechmann are “the same prior art . . . previously . .
`
`. presented to the Office,” the Board should exercise its discretion under Section
`
`325(d) and deny institution of Grounds 4 and 6. See also Neil Ziegmann, N.P.Z.,
`
`IPR2015-01860, Paper 13 at 19 (“[T]he use of the word ‘or’ in ‘prior art or
`
`arguments’ indicates that the presence of previously presented prior art or
`
`arguments is sufficient to invoke Section 325(d).”).
`
`C. Inter Partes Review Proceedings Violate the Constitution.
`The Board should terminate this proceeding because it violates Patent
`
`Owner’s constitutional rights. Because patents are private property rights and
`
`disputes concerning their validity were traditionally decided by courts, patent
`
`validity must be litigated in an Article III court, not before an executive branch
`
`agency. McCormick Harvesting Mach. Co. v. C. Aultman & Co., 169 U.S. 606,
`
`609 (1898). Adversarial challenges to an issued patent—like inter partes
`
`reviews—are also “Suits at common law” for which the Seventh Amendment
`
`guarantees a jury trial. U.S. Const. amend. VII; Markman v. Westview
`
`16
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`Instruments, Inc., 517 U.S. 370, 377 (1996). Moreover, even if inter partes review
`
`
`
`
`
`is constitutional in other circumstances, it is unconstitutional for patents—like the
`
`’213 patent—that issued before passage of the America Invents Act.
`
`The Supreme Court is currently considering the constitutionality of inter
`
`partes reviews in Oil States Energy Services, LLC v. Greene’s Energy Group,
`
`LLC, No. 16-712. Patent Owner presents this constitutional challenge now to
`
`preserve the issue pending the Supreme Court’s decision.
`
` CONCLUSION
`Boehringer’s Petition raises grounds that the Board is already addressing in
`
`other proceedings, and that rest on prior art that the PTO already considered during
`
`prosecution. Allowing Boehringer to raise those redundant arguments in a new
`
`IPR proceeding would waste the Board’s and Patent Owner’s resources, and
`
`present Boehringer with an unfair tactical advantage. Genentech therefore
`
`respectfully requests that the Board exercise its discretion to deny institution of all
`
`grounds pursuant to Section 325(d).
`
`
`
`
`
`17
`
`
`
`
`
`
`
`Date: January 5, 2018
`
`
`
`
`
`
`
`
` IPR2017-02031
`Patent Owner’s Preliminary Response
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`
`/David L. Cavanaugh/
`David L. Cavanaugh
`Registration No. 36,476
`Counsel for Patent Owner
`
`
`
`WILMER CUTLER PICKERING HALE AND DORR LLP
`1875 PENNSYLVANIA AVENUE NW
`WASHINGTON, DC 20006
`TEL: 202-663-6000
`FAX: 202-663-6363
`EMAIL: david.cavanaugh@wilmerhale.com
`
`
`
`18
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-02031
`Patent Owner’s Preliminary Response
`
`CERTIFICATE OF COMPLIANCE
`
`I hereby certify that the foregoing Patent Owner’s Preliminary Response,
`
`contains 3,372 words as measured by the word processing software used to prepare
`
`the document, in compliance with 37 C.F.R. § 42.24(d).
`
`
`
`Dated: January 5, 2018
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/David L. Cavanaugh/
`David L. Cavanaugh
`Registration No. 36,476
`
`19
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-02031
`Patent Owner’s Preliminary Response
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that, on January 5, 2018, I caused a true and correct copy of
`
`the following materials:
`
` Patent Owner’s Preliminary Response
`
` Certificate of Compliance
`
`to be served electronically via electronic mail, as previously agreed by the parties,
`
`on the following attorneys of record:
`
`Ira J. Levy
`GOODWIN PROCTER LLP
`620 Eighth Avenue, New York, NY 10018
`ILevy@goodwinlaw.com
`
`Brian A. Fairchild
`GOODWIN PROCTER LLP
`100 Northern Avenue Boston, MA 02210
`bfairchild@goodwinlaw.com
`
`DG-BI213@goodwinlaw.com
`
`
`/Rebecca A. Whitfield/
`Rebecca A. Whitfield
`Reg. No. 73,756
`Wilmer Cutler Pickering Hale and Dorr LLP
`60 State Street
`Boston, MA 02109
`
`
`20
`
`